Australian Patient Treated With DC Bead LUMI™, the First Commercially Available Radiopaque Drug-Eluting Bead PR Newswire LONDON, January 21, 2019...
BTG and OMNY Partner to Improve Treatment of Snake Bite Victims PR Newswire PHILADELPHIA, January 8, 2019 PHILADELPHIA, January 8, 2019...
BTG Announces National Reimbursement for TheraSphere® in France PR Newswire LONDON, December 21, 2018 LONDON, December 21, 2018 /PRNewswire/...
BTG Announces Global Launch of the ICEfx™ Cryoablation System PR Newswire LONDON, September 20, 2018 LONDON, September 20, 2018 /PRNewswire/...
BTG PLC 15 June 2018 Result of FDA Advisory Committee vote on Elevair(TM) for the treatment of severe emphysema London, UK, 15 June 2018: BTG plc...
ELEVATE Study Aims to Improve Selection Criteria and Outcomes for Patients with Severe Emphysema Treated with the PneumRx™ Endobronchial Coil...
BTG plc: Northwestern University Adopts Y90 TARE with TheraSphere® as First-Line Treatment for HCC Based on experience with 1000 patients over 15...
New Consensus Guidelines Provide Specific Recommendations for Use of Voraxaze® in Patients with Delayed Methotrexate Clearance PR...
First Patient Treated With Microscopic Beads Pre-loaded With a Targeted Cancer Drug and Visible on CT Scans PR Newswire LONDON, October 9, 2017...
Vistogard® and Voraxaze® Added to Revised Guidelines for Stocking of Antidotes in US Hospitals PR Newswire PHILADELPHIA, September 13, 2017...
BTG and SIO Expand Immuno-Oncology / Interventional Oncology Grant Programme Total grant funding available for investigators has been doubled PR...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.